Research graph
References from Baseline Detrusor Overactivity Subtype and Impaired Detrusor Contractility Are Associated With Persistent Detrusor Overactivity After β3‐Adrenoceptor Agonist Add‐On Therapy in Men With Lower Urinary Tract Symptoms. Local targets link to admitted publications; unresolved targets remain external evidence.
Prevalence and Impact on Daily Life of Lower Urinary Tract Symptoms in Japan: Results of the 2023 Japan Community Health Survey (JaCS 2023)
10.1111/iju.15454 · 2024 · External reference
What Is the Most Bothersome Lower Urinary Tract Symptom? Individual‐ and Population‐Level Perspectives for Both Men and Women
10.1016/j.eururo.2014.01.019 · 2014 · External reference
Effect of Bothersome Overactive Bladder Symptoms on Health‐Related Quality of Life, Anxiety, Depression, and Treatment Seeking in the United States: Results From EpiLUTS
10.1016/j.urology.2012.04.004 · 2012 · External reference
Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023
10.1097/ju.0000000000003698 · 2024 · External reference
Summary Paper on the 2026 European Association of Urology Guidelines on the Management of Non‐Neurogenic Male Lower Urinary Tract Symptoms
10.1016/j.eururo.2026.03.020 · 2026 · External reference
Clinical Guidelines for Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
10.1111/iju.13401 · 2017 · External reference
Efficacy and Safety of Mirabegron Versus Placebo Add‐On Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS)
10.1097/ju.0000000000000738 · 2020 · External reference
Mirabegron Add‐On Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men With Lower Urinary Tract Symptoms: A Randomized, Placebo‐Controlled Study (MATCH)
10.1016/j.euf.2019.10.019 · 2020 · External reference
Efficacy and Safety of Vibegron Add‐On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With Alpha(1)‐Blocker Treatment: A Multi‐Center Prospective Randomized Controlled Study (VATON Study)
10.1111/luts.70053 · 2026 · External reference
Urodynamic Efficacy and Safety of Mirabegron Add‐On Treatment With Tamsulosin for Japanese Male Patients With Overactive Bladder
10.1111/luts.12091 · 2016 · External reference
Prevalence and Urodynamic Characteristics of Detrusor Overactivity With Impaired Contractility in the Community‐Dwelling Elderly With Non‐Neurogenic Lower Urinary Tract Symptoms: Is It From a Single or Two Independent Bladder Dysfunctions?
10.4111/icu.20200471 · 2021 · External reference
Urodynamic Characterization of Nonobstructive Voiding Dysfunction in Symptomatic Elderly Men
10.1097/00005392-199907000-00035 · 1999 · External reference
Two Types of Detrusor Underactivity in Men With Nonneurogenic Lower Urinary Tract Symptoms
10.1002/nau.25044 · 2023 · External reference
Impaired Detrusor Contractility in Community‐Dwelling Elderly Presenting With Lower Urinary Tract Symptoms
10.1016/j.urology.2006.11.019 · 2007 · External reference
Responsiveness and Minimal Clinically Important Change in Overactive Bladder Symptom Score
10.1016/j.urology.2011.06.020 · 2011 · External reference
Good Urodynamic Practices: Uroflowmetry, Filling Cystometry, and Pressure‐Flow Studies
10.1002/nau.10066 · 2002 · External reference
The Clinical Significance of the Subtypes of Detrusor Overactivity: A Systematic Review
10.1002/nau.70110 · 2025 · External reference
Urodynamic Characteristics of Different Types of Detrusor Overactivity in Patients With Benign Prostatic Obstruction
10.3389/fruro.2026.1845544 · 2026 · External reference
Effects of Different Urodynamic Characteristics on Therapeutic Outcomes of Overactive Bladder Medication in a Real‐Life Clinical Practice
10.4103/tcmj.tcmj_264_20 · 2022 · External reference
Detrusor Hyperactivity With Impaired Contractile Function. An Unrecognized but Common Cause of Incontinence in Elderly Patients
10.1001/jama.1987.03390220074024 · 1987 · External reference
Atherosclerosis‐Induced Chronic Ischemia Causes Bladder Fibrosis and Non‐Compliance in the Rabbit
10.1016/s0022-5347(05)68995-1 · 1999 · External reference
Progressive Changes in Detrusor Function and Micturition Patterns With Chronic Bladder Ischemia
10.4111/icu.2016.57.4.249 · 2016 · External reference
Chronic Bladder Ischemia and Oxidative Stress: New Pharmacotherapeutic Targets for Lower Urinary Tract Symptoms
10.1111/iju.12652 · 2015 · External reference
Persistent Detrusor Overactivity After Transurethral Resection of the Prostate Is Associated With Reduced Perfusion of the Urinary Bladder
10.1111/j.1464-410x.2006.06735.x · 2007 · External reference
Can We Predict Which Patients Will Experience Resolution of Detrusor Overactivity After Transurethral Resection of the Prostate?
10.1016/j.juro.2014.12.095 · 2015 · External reference
Influence of Detrusor Overactivity on Storage Symptoms Following Potassium‐Titanyl‐Phosphate Photoselective Vaporization of the Prostate
10.1016/j.urology.2009.09.065 · 2010 · External reference
